Oxidative Stress in SLE T Cells, Is NRF2 Really the Target to Treat?

Kim Ohl1, Klaus Tenbrock1

  • 1Department of Pediatrics, Pediatric Rheumatology, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Insights

Systemic lupus erythematosus (SLE) involves T cell damage from oxidative stress, creating harmful Th17 cells. Targeting the NRF2/Keap1 antioxidant pathway may treat SLE, but requires understanding cell-specific effects.

Area of Science:

  • Immunology and Molecular Medicine
  • Cellular Biology
  • Autoimmune Diseases

Background:

  • Oxidative stress significantly damages T cells in patients with systemic lupus erythematosus (SLE).
  • This cellular damage contributes to the development of pathogenic T helper 17 (Th17) cells.
  • The Nuclear factor erythroid 2-related factor 2 (NRF2)/Kelch-like ECH-associated protein 1 (Keap1) pathway is crucial for cellular defense against oxidative stress.

Purpose of the Study:

  • To review the current understanding of oxidative stress in T cells within the context of SLE.
  • To explore the pathophysiological role of oxidative stress and the NRF2/Keap1 pathway in SLE.
  • To discuss the therapeutic implications of targeting the NRF2/Keap1 pathway for SLE treatment.

Main Methods:

  • Literature review of studies on oxidative stress in SLE T cells.
  • Analysis of the NRF2/Keap1 pathway's role in cellular protection and its relevance to SLE.
  • Examination of evidence regarding cell-specific and tissue-specific effects of NRF2 modulation.

Main Results:

  • Oxidative stress is a key factor in T cell dysfunction and pathogenesis in SLE.
  • The NRF2/Keap1 pathway is a critical endogenous antioxidant system.
  • Potential therapeutic targeting of NRF2 in SLE is complicated by context-dependent effects.

Conclusions:

  • Understanding oxidative stress in SLE T cells is vital for developing effective therapies.
  • The NRF2/Keap1 pathway presents a promising therapeutic target, but its precise role requires further investigation.
  • Cell- and tissue-specific differences in NRF2 activity must be considered for successful SLE treatment strategies.